Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
125 hedge funds and large institutions have $35.3M invested in Sanofi Contingent Value Rights in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 16 closing their positions.
4% less funds holding
Funds holding: 130 → 125 (-5)
19% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 27
36% less capital inflows, than outflows
Capital inflows: $4.98M | Capital outflows: $7.75M
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
+$929K |
| 2 |
Park West Asset Management
San Francisco,
California
|
+$864K |
| 3 |
SM
Scoggin Management
New York
|
+$743K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
+$483K |
| 5 |
Citigroup
New York
|
+$372K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Abrams Capital Management
Boston,
Massachusetts
|
-$3.96M |
| 2 |
Standard Investments
New York
|
-$819K |
| 3 |
Putnam Investments
Boston,
Massachusetts
|
-$427K |
| 4 |
AGCJ
Alden Global Capital (Jersey)
St. Helier,
Jersey
|
-$425K |
| 5 |
Whitebox Advisors
Minneapolis,
Minnesota
|
-$360K |
GCVRZ Hedge Fund Activity: Q1 2014 in Review
125 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2014, worth a combined $35.3M — down 15% from $41.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 7 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 22 added.
The largest buyer was Gruss Capital Management, adding an estimated $929K. The largest seller was Abrams Capital Management, exiting entirely with an estimated $3.96M sold.
- 125 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2014, down from 130 in Q4 2013.
- Funds reported $35.3M of Sanofi Contingent Value Rights stock for Q1 2014, down 15% quarter-over-quarter.
- 7 funds opened new Sanofi Contingent Value Rights positions in Q1 2014 and 16 closed out, a net change of -9 holders.
- The largest Sanofi Contingent Value Rights buyer in Q1 2014 was Gruss Capital Management, an estimated $929K added.
- The largest Sanofi Contingent Value Rights seller in Q1 2014 was Abrams Capital Management, an estimated $3.96M sold.
Based on aggregated 13F filings for Q1 2014.